About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 187204, 15 pages
http://dx.doi.org/10.1155/2013/187204
Review Article

The Inflammatory Microenvironment in Hepatocellular Carcinoma: A Pivotal Role for Tumor-Associated Macrophages

Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Via Vetoio, Coppito II, 67100 L’Aquila, Italy

Received 8 June 2012; Accepted 13 August 2012

Academic Editor: Elba Vazquez

Copyright © 2013 Daria Capece et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Yang, I. Nakamura, and L. R. Roberts, “The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets,” Seminars in Cancer Biology, vol. 21, no. 1, pp. 35–43, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Bruix, L. Boix, M. Sala, and J. M. Llovet, “Focus on hepatocellular carcinoma,” Cancer Cell, vol. 5, no. 3, pp. 215–219, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Berasain, J. Castillo, M. J. Perugorria, M. U. Latasa, J. Prieto, and M. A. Avila, “Inflammation and liver cancer: new molecular links,” Annals of the New York Academy of Sciences, vol. 1155, pp. 206–221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Porta, E. Riboldi, and A. Sica, “Mechanisms linking pathogens-associated inflammation and cancer,” Cancer Letters, vol. 305, no. 2, pp. 250–262, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Budhu and W. W. Xin, “The role of cytokines in hepatocellular carcinoma,” Journal of Leukocyte Biology, vol. 80, no. 6, pp. 1197–1213, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. G. C. Leonardi, S. Candido, M. Cervello, et al., “The tumor microenvironment in hepatocellular carcinoma,” International Journal of Oncology, vol. 40, no. 6, pp. 1733–1747, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Pikarsky, R. M. Porat, I. Stein et al., “NF-κB functions as a tumour promoter in inflammation-associated cancer,” Nature, vol. 431, no. 7007, pp. 461–466, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Luedde and R. F. Schwabe, “NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma,” Nature Reviews Gastroenterology and Hepatology, vol. 8, no. 2, pp. 108–118, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Mantovani, G. Germano, F. Marchesi, M. Locatelli, and S. K. Biswas, “Cancer-promoting tumor-associated macrophages: new vistas and open questions,” European Journal of Immunology, vol. 41, no. 9, pp. 2522–2525, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Solinas, G. Germano, A. Mantovani, and P. Allavena, “Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation,” Journal of Leukocyte Biology, vol. 86, no. 5, pp. 1065–1073, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Porta, P. Larghi, M. Rimoldi et al., “Cellular and molecular pathways linking inflammation and cancer,” Immunobiology, vol. 214, no. 9-10, pp. 761–777, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Mantovani and A. Sica, “Macrophages, innate immunity and cancer: balance, tolerance, and diversity,” Current Opinion in Immunology, vol. 22, no. 2, pp. 231–237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Z. Qian and J. W. Pollard, “Macrophage diversity enhances tumor progression and metastasis,” Cell, vol. 141, no. 1, pp. 39–51, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Mantovani, S. Sozzani, M. Locati, P. Allavena, and A. Sica, “Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes,” Trends in Immunology, vol. 23, no. 11, pp. 549–555, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Gordon and P. R. Taylor, “Monocyte and macrophage heterogeneity,” Nature Reviews Immunology, vol. 5, no. 12, pp. 953–964, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. S. K. Biswas and A. Mantovani, “Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm,” Nature Immunology, vol. 11, no. 10, pp. 889–896, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Movahedi, D. Laoui, C. Gysemans et al., “Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes,” Cancer Research, vol. 70, no. 14, pp. 5728–5739, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. R. D. Stout, C. Jiang, B. Matta, I. Tietzel, S. K. Watkins, and J. Suttles, “Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences,” The Journal of Immunology, vol. 175, no. 1, pp. 342–349, 2005. View at Scopus
  19. D. I. Gabrilovich and S. Nagaraj, “Myeloid-derived suppressor cells as regulators of the immune system,” Nature Reviews Immunology, vol. 9, no. 3, pp. 162–174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. C. I. Chang, J. C. Liao, and L. Kuo, “Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity,” Cancer Research, vol. 61, no. 3, pp. 1100–1106, 2001. View at Scopus
  21. L. E. Davel, M. A. Jasnis, E. De la Torre et al., “Arginine metabolic pathways involved in the modulation of tumor-induced angiogenesis by macrophages,” FEBS Letters, vol. 532, no. 1-2, pp. 216–220, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. J. W. Pollard, “Tumour-educated macrophages promote tumour progression and metastasis,” Nature Reviews Cancer, vol. 4, no. 1, pp. 71–78, 2004. View at Scopus
  23. C. E. Lewis and J. W. Pollard, “Distinct role of macrophages in different tumor microenvironments,” Cancer Research, vol. 66, no. 2, pp. 605–612, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Sica and V. Bronte, “Altered macrophage differentiation and immune dysfunction in tumor development,” The Journal of Clinical Investigation, vol. 117, no. 5, pp. 1155–1166, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Kusmartsev and D. I. Gabrilovich, “STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion,” The Journal of Immunology, vol. 174, no. 8, pp. 4880–4891, 2005. View at Scopus
  26. C. S. Tsai, F. H. Chen, C. C. Wang et al., “Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth,” International Journal of Radiation Oncology Biology Physics, vol. 68, no. 2, pp. 499–507, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Sugai, K. Kono, A. Takahashi et al., “Characteristic alteration of monocytes with increased intracellular IL-10 and IL-12 in patients with advanced-stage gastric cancer,” Journal of Surgical Research, vol. 116, no. 2, pp. 277–287, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Hagemann, J. Wilson, F. Burke et al., “Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype,” The Journal of Immunology, vol. 176, no. 8, pp. 5023–5032, 2006. View at Scopus
  29. S. K. Biswas, L. Gangi, S. Paul et al., “A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-κB and enhanced IRF-3/STAT1 activation),” Blood, vol. 107, no. 5, pp. 2112–2122, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. D. M. Kuang, Y. Wu, N. Chen, J. Cheng, S. M. Zhuang, and L. Zheng, “Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes,” Blood, vol. 110, no. 2, pp. 587–595, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Wu and L. Zheng, “Dynamic education of macrophages in different areas of human tumors,” Cancer Microenvironment. In press. View at Publisher · View at Google Scholar · View at Scopus
  32. D. M. Kuang, C. Peng, Q. Zhao, Y. Wu, M. S. Chen, and L. Zheng, “Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells,” Hepatology, vol. 51, no. 1, pp. 154–164, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Pietras, J. Pahler, G. Bergers, and D. Hanahan, “Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting,” PLoS Medicine, vol. 5, no. 1, article e19, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. X. D. Zhu, J. B. Zhang, P. Y. Zhuang et al., “High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma,” Journal of Clinical Oncology, vol. 26, no. 16, pp. 2707–2716, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Benetti, A. Berenzi, M. Gambarotti et al., “Transforming growth factor-β1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium,” Cancer Research, vol. 68, no. 20, pp. 8626–8634, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Takai, A. Kato, C. Kato et al., “The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma,” Liver International, vol. 29, no. 7, pp. 1056–1064, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. J. B. Jia, W. Q. Wang, H. C. Sun et al., “High expression of macrophage colony-stimulating factor-1 receptor in peritumoral liver tissue is associated with poor outcome in hepatocellular carcinoma after curative resection,” Oncologist, vol. 15, no. 7, pp. 732–743, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Haybaeck, N. Zeller, M. J. Wolf et al., “A lymphotoxin-driven pathway to hepatocellular carcinoma,” Cancer Cell, vol. 16, no. 4, pp. 295–308, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. T. A. Chen, J. L. Wang, S. W. Hung, C. L. Chu, Y. C. Cheng, and S. M. Liang, “Recombinant VP1, an akt inhibitor, suppresses progression of hepatocellular carcinoma by inducing apoptosis and modulation of CCL2 production,” PLoS ONE, vol. 6, no. 8, Article ID e23317, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Sakai, M. Honda, H. Fujinaga et al., “Common transcriptional signature of tumor-infiltrating mononuclear inflammatory cells and peripheral blood mononuclear cells in hepatocellular carcinoma patients,” Cancer Research, vol. 68, no. 24, pp. 10267–10279, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Budhu, M. Forgues, Q. H. Ye et al., “Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment,” Cancer Cell, vol. 10, no. 2, pp. 99–111, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Zhou, T. Ding, W. Pan, L. Y. Zhu, A. Li, and L. Zheng, “Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients,” International Journal of Cancer, vol. 125, no. 7, pp. 1640–1648, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. D. M. Kuang, Q. Zhao, C. Peng et al., “Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1,” The Journal of Experimental Medicine, vol. 206, no. 6, pp. 1327–1337, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Ding, J. Xu, F. Wang et al., “High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection,” Human Pathology, vol. 40, no. 3, pp. 381–389, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. W. Li, S. J. Qiu, J. Fan et al., “Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection,” Journal of Cancer Research and Clinical Oncology, vol. 135, no. 3, pp. 439–449, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. V. Chew, C. Tow, M. Teo et al., “Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients,” Journal of Hepatology, vol. 52, no. 3, pp. 370–379, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. J. B. Wyckoff, Y. Wang, E. Y. Lin et al., “Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors,” Cancer Research, vol. 67, no. 6, pp. 2649–2656, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. J. S. Lee, J. Heo, L. Libbrecht et al., “A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells,” Nature Medicine, vol. 12, no. 4, pp. 410–416, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. Hoshida, A. Villanueva, M. Kobayashi et al., “Gene expression in fixed tissues and outcome in hepatocellular carcinoma,” The New England Journal of Medicine, vol. 359, no. 19, pp. 1995–2004, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Maeda, H. Kamata, J. L. Luo, H. Leffert, and M. Karin, “IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis,” Cell, vol. 121, no. 7, pp. 977–990, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. W. E. Naugler, T. Sakurai, S. Kim et al., “Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production,” Science, vol. 317, no. 5834, pp. 121–124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. E. J. Park, J. H. Lee, G. Y. Yu et al., “Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression,” Cell, vol. 140, no. 2, pp. 197–208, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. V. W. S. Wong, J. Yu, A. S. L. Cheng et al., “High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B,” International Journal of Cancer, vol. 124, no. 12, pp. 2766–2770, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Nakagawa, S. Maeda, H. Yoshida et al., “Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences,” International Journal of Cancer, vol. 125, no. 10, pp. 2264–2269, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Y. Hsia, T. I. Huo, S. Y. Chiang et al., “Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma,” European Journal of Surgical Oncology, vol. 33, no. 2, pp. 208–212, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. J. S. Reichner, J. A. Mulligan, R. Spisni, E. A. Sotomayor, J. E. Albina, and K. I. Bland, “Effect of IL-6 overexpression on the metastatic potential of rat hepatocellular carcinoma cells,” Annals of Surgical Oncology, vol. 5, no. 3, pp. 279–286, 1998. View at Publisher · View at Google Scholar · View at Scopus
  57. U. Coskun, N. Bukan, B. Sancak et al., “Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions,” Neoplasma, vol. 51, no. 3, pp. 209–213, 2004. View at Scopus
  58. Y. Tang, K. Kitisin, W. Jogunoori et al., “Progenitor/stem cells give rise to liver cancer due to aberrant TGF-β and IL-6 signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 7, pp. 2445–2450, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Werno, H. Menrad, A. Weigert et al., “Knockout of HIF-1α in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses,” Carcinogenesis, vol. 31, no. 10, pp. 1863–1872, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. D. R. Littman and A. Y. Rudensky, “Th17 and regulatory T cells in mediating and restraining inflammation,” Cell, vol. 140, no. 6, pp. 845–858, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. J. P. Zhang, J. Yan, J. Xu et al., “Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients,” Journal of Hepatology, vol. 50, no. 5, pp. 980–989, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. N. Fausto, J. S. Campbell, and K. J. Riehle, “Liver regeneration,” Hepatology, vol. 43, no. 1, pp. S45–S53, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. R. M. Gallucci, P. P. Simeonova, W. Toriumi, and M. I. Luster, “TNF-α regulates transforming growth factor-α expression in regenerating murine liver and isolated hepatocytes,” The Journal of Immunology, vol. 164, no. 2, pp. 872–878, 2000. View at Scopus
  64. B. D. Cosgrove, C. Cheng, J. R. Pritchard, D. B. Stolz, D. A. Lauffenburger, and L. G. Griffith, “An inducible autocrine cascade regulates rat hepatocyte proliferation and apoptosis responses to tumor necrosis factor-α,” Hepatology, vol. 48, no. 1, pp. 276–288, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. N. M. Wheelhouse, Y. S. Chan, S. E. Gillies et al., “TNF-alpha induced DNA damage in primary murine hepatocytes,” International Journal of Molecular Medicine, vol. 12, no. 6, pp. 889–894, 2003.
  66. Y. Wang, W. Wang, L. Wang, X. Wang, and J. Xia, “Regulatory mechanisms of interleukin-8 production induced by tumour necrosis factor-α in human hepatocellular carcinoma cells,” Journal of Cellular and Molecular Medicine, vol. 16, no. 3, pp. 496–506, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. L. Mueller, F. A. Goumas, M. Affeldt et al., “Stromal fibroblasts in colorectal liver metastases originate from resident fibroblasts and generate an inflammatory microenvironment,” American Journal of Pathology, vol. 171, no. 5, pp. 1608–1618, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. K. Shiraki, T. Yamanaka, H. Inoue et al., “Expression of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma,” International Journal of Oncology, vol. 26, no. 5, pp. 1273–1281, 2005. View at Scopus
  69. W. Ke, I. Kryczek, L. Chen, W. Zou, and T. H. Welling, “Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions,” Cancer Research, vol. 69, no. 20, pp. 8067–8075, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. R. M. Talaat, A. A. Esmail, R. Elwakil, A. A. Gurgis, and M. I. Nasr, “Tumor necrosis factor-alpha -308G/A polymorphism and risk of hepatocellular carcinoma in hepatitis C virus-infected patients,” Chinese Journal of Cancer, vol. 31, no. 1, pp. 29–35, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. J. Chen, G. Li, H. Meng, et al., “Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas,” Cancer Immunology, Immunotherapy, vol. 61, no. 1, pp. 101–108, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. M. J. Ju, S. J. Qiu, J. Fan et al., “Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection,” American Journal of Clinical Pathology, vol. 131, no. 4, pp. 498–510, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. Q. Gao, S. J. Qiu, J. Fan et al., “Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection,” Journal of Clinical Oncology, vol. 25, no. 18, pp. 2586–2593, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Fu, D. Xu, Z. Liu et al., “Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients,” Gastroenterology, vol. 132, no. 7, pp. 2328–2339, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. X. Shen, N. Li, H. Li, T. Zhang, F. Wang, and Q. Li, “Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma,” Journal of Cancer Research and Clinical Oncology, vol. 136, no. 11, pp. 1745–1754, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. E. Ryschich, P. Lizdenis, C. Ittrich et al., “Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma,” Cancer Research, vol. 66, no. 1, pp. 198–211, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. Q. Zhao, X. Xiao, Y. Wu et al., “Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients,” European Journal of Immunology, vol. 41, no. 8, pp. 2314–2322, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. D. M. Kuang, C. Peng, Q. Zhao et al., “Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients,” The Journal of Immunology, vol. 185, no. 3, pp. 1544–1549, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. H. Uchida, Y. Iwashita, A. Sasaki et al., “Chemokine receptor CCR6 as a prognostic factor after hepatic resection for hepatocellular carcinoma,” Journal of Gastroenterology and Hepatology, vol. 21, no. 1, pp. 161–168, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. Y.-T. Shih, M.-C. Wang, H.-H. Peng, et al., “Modulation of chemotactic and pro-inflammatory activities of endothelial progenitor cells by hepatocellular carcinoma,” Cellular Signalling, vol. 24, no. 3, pp. 779–793, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. A. Sutton, V. Friand, S. Brulé-Donneger et al., “Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion,” Molecular Cancer Research, vol. 5, no. 1, pp. 21–33, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. H. Liu, Z. Pan, A. Li et al., “Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells,” Cellular and Molecular Immunology, vol. 5, no. 5, pp. 373–378, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. H. Chu, H. Zhou, Y. Liu, X. Liu, Y. Hu, and J. Zhang, “Functional expression of CXC chemokine recepter-4 mediates the secretion of matrix metalloproteinases from mouse hepatocarcinoma cell lines with different lymphatic metastasis ability,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 1, pp. 197–205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. C. C. Schimanski, R. Bahre, I. Gockel et al., “Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4,” British Journal of Cancer, vol. 95, no. 2, pp. 210–217, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. Z. Liu, L. Yang, J. Xu, X. Zhang, and B. Wang, “Enhanced expression and clinical significance of chemokine receptor CXCR2 in hepatocellular carcinoma,” Journal of Surgical Research, vol. 166, no. 2, pp. 241–246, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. K. Breuhahn, T. Longerich, and P. Schirmacher, “Dysregulation of growth factor signaling in human hepatocellular carcinoma,” Oncogene, vol. 25, no. 27, pp. 3787–3800, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. S. H. Peng, H. Deng, J. F. Yang et al., “Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues,” World Journal of Gastroenterology, vol. 11, no. 41, pp. 6521–6524, 2005. View at Scopus
  88. C. Drucker, W. Parzefall, O. Teufelhofer et al., “Non-parenchymal liver cells support the growth advantage in the first stages of hepatocarcinogenesis,” Carcinogenesis, vol. 27, no. 1, pp. 152–161, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. G. Giannelli, A. Mazzocca, E. Fransvea, M. Lahn, and S. Antonaci, “Inhibiting TGF-β signaling in hepatocellular carcinoma,” Biochimica et Biophysica Acta, vol. 1815, no. 2, pp. 214–223, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. B. F. Zamarron and W. Chen, “Dual roles of immune cells and their factors in cancer development and progression,” International Journal of Biological Sciences, vol. 7, no. 5, pp. 651–658, 2011. View at Scopus
  91. E. Volpe, N. Servant, R. Zollinger et al., “A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses,” Nature Immunology, vol. 9, no. 6, pp. 650–657, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. N. Manel, D. Unutmaz, and D. R. Littman, “The differentiation of human TH-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt,” Nature Immunology, vol. 9, no. 6, pp. 641–649, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. E. Fransvea, A. Mazzocca, S. Antonaci, and G. Giannelli, “Targeting transforming growth factor (TGF)-βRI inhibits activation of β1 integrin and blocks vascular invasion in hepatocellular carcinoma,” Hepatology, vol. 49, no. 3, pp. 839–850, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. G. Giannelli, E. Fransvea, F. Marinosci et al., “Transforming growth factor-β1 triggers hepatocellular carcinoma invasiveness via α3β1 integrin,” American Journal of Pathology, vol. 161, no. 1, pp. 183–193, 2002. View at Scopus
  95. A. Mazzocca, E. Fransvea, G. Lavezzari, S. Antonaci, and G. Giannelli, “Inhibition of transforming growth factor β receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation,” Hepatology, vol. 50, no. 4, pp. 1140–1151, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. E. Fransvea, A. Mazzocca, A. Santamato, A. Azzariti, S. Antonaci, and G. Giannelli, “Kinase activation profile associated with TGF-β-dependent migration of HCC cells: a preclinical study,” Cancer Chemotherapy and Pharmacology, vol. 68, no. 1, pp. 79–86, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. G. Giannelli, C. Bergamini, E. Fransvea, C. Sgarra, and S. Antonaci, “Laminin-5 with transforming growth factor-β1 induces epithelial to mesenchymal transition in hepatocellular carcinoma,” Gastroenterology, vol. 129, no. 5, pp. 1375–1383, 2005. View at Publisher · View at Google Scholar · View at Scopus
  98. F. Van Zijl, M. Mair, A. Csiszar et al., “Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge,” Oncogene, vol. 28, no. 45, pp. 4022–4033, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. J. Wu, N. Y. Ru, Y. Zhang et al., “HAb18G/CD147 promotes epithelial-mesenchymal transition through TGF-β signaling and is transcriptionally regulated by Slug,” Oncogene, vol. 30, no. 43, pp. 4410–4427, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. B. Wang, S. H. Hsu, S. Majumder et al., “TGFβ-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3,” Oncogene, vol. 29, no. 12, pp. 1787–1797, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. S. Huang, X. He, J. Ding et al., “Upregulation of miR-23a~27a~24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells,” International Journal of Cancer, vol. 123, no. 4, pp. 972–978, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. P. Bedossa, E. Peltier, B. Terris, D. Franco, and T. Poynard, “Transforming growth factor-beta 1 (TGF-β1) and TGF-β1 receptors in normal, cirrhotic, and neoplastic human livers,” Hepatology, vol. 21, no. 3, pp. 760–766, 1995. View at Scopus
  103. Y. Shirai, S. Kawata, S. Tamura et al., “Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma: comparison with chronic liver diseases,” Cancer, vol. 73, no. 9, pp. 2275–2279, 1994. View at Scopus
  104. K. Okumoto, E. Hattori, K. Tamura et al., “Possible contribution of circulating transforming growth factor-β1 to immunity and prognosis in unresectable hepatocellular carcinoma,” Liver International, vol. 24, no. 1, pp. 21–28, 2004. View at Scopus
  105. T. Mamiya, K. Yamazaki, Y. Masugi et al., “Reduced transforming growth factor-β receptor II expression in hepatocellular carcinoma correlates with intrahepatic metastasis,” Laboratory Investigation, vol. 90, no. 9, pp. 1339–1345, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. K. K. Hirschi and P. A. D'Amore, “Control of angiogenesis by the pericyte: molecular mechanisms and significance,” EXS, vol. 79, pp. 419–428, 1997. View at Scopus
  107. J. S. Campbell, S. D. Hughes, D. G. Gilbertson et al., “Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 9, pp. 3389–3394, 2005. View at Publisher · View at Google Scholar · View at Scopus
  108. M. J. Perugorria, M. U. Latasa, A. Nicou et al., “The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis,” Hepatology, vol. 48, no. 4, pp. 1251–1261, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. C. Berasain, J. Castillo, J. Prieto, and M. A. Avila, “New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system,” Liver International, vol. 27, no. 2, pp. 174–185, 2007. View at Publisher · View at Google Scholar · View at Scopus
  110. E. Schiffer, C. Housset, W. Cacheux et al., “Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis,” Hepatology, vol. 41, no. 2, pp. 307–314, 2005. View at Publisher · View at Google Scholar · View at Scopus
  111. J. Tabernero, “The role of VEGF and EGFR inhibition: implications for combining Anti-VEGF and Anti-EGFR Agents,” Molecular Cancer Research, vol. 5, no. 3, pp. 203–220, 2007. View at Publisher · View at Google Scholar · View at Scopus
  112. J. C. Yang, C. F. Teng, H. C. Wu et al., “Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis,” Hepatology, vol. 49, no. 6, pp. 1962–1971, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. A. X. Zhu, D. G. Duda, M. Ancukiewicz et al., “Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value,” Clinical Cancer Research, vol. 17, no. 4, pp. 918–927, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. S.-D. Wu, Y.-S. Ma, Y. Fang, L.-L. Liu, D. Fu, and X.-Z. Shen, “Role of the microenvironment in hepatocellular carcinoma development and progression,” Cancer Treatment Reviews, vol. 38, no. 3, pp. 218–225, 2012. View at Publisher · View at Google Scholar · View at Scopus
  115. S. Arii, M. Mise, T. Harada et al., “Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential,” Hepatology, vol. 24, no. 2, pp. 316–322, 1996. View at Publisher · View at Google Scholar · View at Scopus
  116. M. Maatta, Y. Soini, A. Liakka, and H. Autio-Harmainen, “Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis,” Clinical Cancer Research, vol. 6, no. 7, pp. 2726–2734, 2000. View at Scopus
  117. J. C. H. Cheng, C. H. Chou, M. L. Kuo, and C. Y. Hsieh, “Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-κB signal transduction pathway,” Oncogene, vol. 25, no. 53, pp. 7009–7018, 2006. View at Publisher · View at Google Scholar · View at Scopus
  118. Y. Sakamoto, K. Mafune, M. Mori et al., “Overexpression of MMP-9 correlates with growth of small hepatocellular carcinoma,” International Journal of Oncology, vol. 17, no. 2, pp. 237–243, 2000. View at Scopus
  119. M. Roderfeld, T. Rath, F. Lammert, C. Dierkes, J. Graf, and E. Roeb, “Innovative immunohistochemistry identifies MMP-9 expressing macrophages at the invasive front of murine HCC,” World Journal of Hepatology, vol. 2, no. 5, pp. 175–179, 2010.
  120. K. Kohga, T. Tatsumi, T. Takehara et al., “Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma,” Journal of Hepatology, vol. 52, no. 6, pp. 872–879, 2010. View at Publisher · View at Google Scholar · View at Scopus
  121. L. E. Littlepage, M. D. Sternlicht, N. Rougier et al., “Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression,” Cancer Research, vol. 70, no. 6, pp. 2224–2234, 2010. View at Publisher · View at Google Scholar · View at Scopus
  122. Q. Yu and I. Stamenkovic, “Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion,” Genes and Development, vol. 13, no. 1, pp. 35–48, 1999. View at Scopus
  123. V. Takafuji, M. Forgues, E. Unsworth, P. Goldsmith, and X. W. Wang, “An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma,” Oncogene, vol. 26, no. 44, pp. 6361–6371, 2007. View at Publisher · View at Google Scholar · View at Scopus
  124. H. Zhang, Q. H. Ye, N. Ren et al., “The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma,” Journal of Cancer Research and Clinical Oncology, vol. 132, no. 11, pp. 709–717, 2006. View at Publisher · View at Google Scholar · View at Scopus
  125. S. K. Ramaiah and S. Rittling, “Reviews: pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer,” Toxicological Sciences, vol. 103, no. 1, pp. 4–13, 2008. View at Publisher · View at Google Scholar · View at Scopus
  126. J. Kim, S. S. Ki, S. D. Lee et al., “Elevated plasma osteopontin levels in patients with hepatocellular carcinoma,” American Journal of Gastroenterology, vol. 101, no. 9, pp. 2051–2059, 2006. View at Publisher · View at Google Scholar · View at Scopus
  127. Q. H. Ye, L. X. Qin, M. Forgues et al., “Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning,” Nature Medicine, vol. 9, no. 4, pp. 416–423, 2003. View at Publisher · View at Google Scholar · View at Scopus
  128. J. Leng, C. Han, A. J. Demetris, G. K. Michalopoulos, and T. Wu, “Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis,” Hepatology, vol. 38, no. 3, pp. 756–768, 2003. View at Publisher · View at Google Scholar · View at Scopus
  129. M. Cervello, D. Foderà, A. M. Florena et al., “Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis,” World Journal of Gastroenterology, vol. 11, no. 30, pp. 4638–4643, 2005. View at Scopus
  130. Q. Zheng, Z. Y. Tang, Q. Xue, D. R. Shi, H. Y. Song, and H. B. Tang, “Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor,” Journal of Cancer Research and Clinical Oncology, vol. 126, no. 11, pp. 641–646, 2000. View at Scopus
  131. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-related inflammation,” Nature, vol. 454, no. 7203, pp. 436–444, 2008. View at Publisher · View at Google Scholar · View at Scopus
  132. M. Karin, “Nuclear factor-κB in cancer development and progression,” Nature, vol. 441, no. 7092, pp. 431–436, 2006. View at Publisher · View at Google Scholar · View at Scopus
  133. G. Bonizzi and M. Karin, “The two NF-κB activation pathways and their role in innate and adaptive immunity,” Trends in Immunology, vol. 25, no. 6, pp. 280–288, 2004. View at Publisher · View at Google Scholar · View at Scopus
  134. T. Luedde, N. Beraza, V. Kotsikoris et al., “Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma,” Cancer Cell, vol. 11, no. 2, pp. 119–132, 2007. View at Publisher · View at Google Scholar · View at Scopus
  135. T. Sakurai, G. He, A. Matsuzawa et al., “Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis,” Cancer Cell, vol. 14, no. 2, pp. 156–165, 2008. View at Publisher · View at Google Scholar · View at Scopus
  136. A. Saccani, T. Schioppa, C. Porta et al., “p50 nuclear factor-κB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance,” Cancer Research, vol. 66, no. 23, pp. 11432–11440, 2006. View at Publisher · View at Google Scholar · View at Scopus
  137. C. Guiducci, A. P. Vicari, S. Sangaletti, G. Trinchieri, and M. P. Colombo, “Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection,” Cancer Research, vol. 65, no. 8, pp. 3437–3446, 2005. View at Scopus
  138. T. Hagemann, T. Lawrence, I. McNeish et al., ““Re-educating” tumor-associated macrophages by targeting NF-κB,” The Journal of Experimental Medicine, vol. 205, no. 6, pp. 1261–1268, 2008. View at Publisher · View at Google Scholar · View at Scopus
  139. T. Hagemann, S. K. Biswas, T. Lawrence, A. Sica, and C. E. Lewis, “Regulation of macrophage function in tumors: the multifaceted role of NF-κB,” Blood, vol. 113, no. 14, pp. 3139–3146, 2009. View at Publisher · View at Google Scholar · View at Scopus
  140. F. Balkwill and A. Mantovani, “Inflammation and cancer: back to Virchow?” The Lancet, vol. 357, no. 9255, pp. 539–545, 2001. View at Publisher · View at Google Scholar · View at Scopus
  141. A. Mantovani, A. Sica, and M. Locati, “New vistas on macrophage differentiation and activation,” European Journal of Immunology, vol. 37, no. 1, pp. 14–16, 2007. View at Publisher · View at Google Scholar · View at Scopus
  142. A. Sica, P. Allavena, and A. Mantovani, “Cancer related inflammation: the macrophage connection,” Cancer Letters, vol. 267, no. 2, pp. 204–215, 2008. View at Publisher · View at Google Scholar · View at Scopus
  143. D. F. Calvisi, “Dr. Jekyll and Mr. Hyde: a paradoxical oncogenic and tumor suppressive role of signal transducer and activator of transcription 3 in liver cancer,” Hepatology, vol. 54, no. 1, pp. 9–12, 2011. View at Publisher · View at Google Scholar · View at Scopus
  144. H. Dalwadi, K. Krysan, N. Heuze-Vourc'h et al., “Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer,” Clinical Cancer Research, vol. 11, no. 21, pp. 7674–7682, 2005. View at Publisher · View at Google Scholar · View at Scopus
  145. M. Kortylewski, M. Kujawski, T. Wang et al., “Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity,” Nature Medicine, vol. 11, no. 12, pp. 1314–1321, 2005. View at Publisher · View at Google Scholar · View at Scopus
  146. M. Kortylewski, H. Xin, M. Kujawski et al., “Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment,” Cancer Cell, vol. 15, no. 2, pp. 114–123, 2009. View at Publisher · View at Google Scholar · View at Scopus
  147. H. Yu, M. Kortylewski, and D. Pardoll, “Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment,” Nature Reviews Immunology, vol. 7, no. 1, pp. 41–51, 2007. View at Publisher · View at Google Scholar · View at Scopus
  148. G. He and M. Karin, “NF-κB and STAT3- key players in liver inflammation and cancer,” Cell Research, vol. 21, no. 1, pp. 159–168, 2011. View at Publisher · View at Google Scholar · View at Scopus
  149. D. F. Calvisi, S. Ladu, A. Gorden et al., “Ubiquitous activation of Ras and Jak/Stat pathways in human HCC,” Gastroenterology, vol. 130, no. 4, pp. 1117–1128, 2006. View at Publisher · View at Google Scholar · View at Scopus
  150. E. Wurmbach, Y. B. Chen, G. Khitrov et al., “Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma,” Hepatology, vol. 45, no. 4, pp. 938–947, 2007. View at Publisher · View at Google Scholar · View at Scopus
  151. G. He, G. Y. Yu, V. Temkin et al., “Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation,” Cancer Cell, vol. 17, no. 3, pp. 286–297, 2010. View at Publisher · View at Google Scholar · View at Scopus
  152. T. Yoshida, H. Ogata, M. Kamio et al., “SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis,” The Journal of Experimental Medicine, vol. 199, no. 12, pp. 1701–1707, 2004. View at Publisher · View at Google Scholar · View at Scopus
  153. K. J. Riehle, J. S. Campbell, R. S. McMahan et al., “Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3,” The Journal of Experimental Medicine, vol. 205, no. 1, pp. 91–103, 2008. View at Publisher · View at Google Scholar · View at Scopus
  154. H. Ogata, T. Kobayashi, T. Chinen et al., “Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis,” Gastroenterology, vol. 131, no. 1, pp. 179–193, 2006. View at Publisher · View at Google Scholar · View at Scopus
  155. Y. Liu, A. Liu, Z. Xu et al., “XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells,” Apoptosis, vol. 16, no. 5, pp. 502–510, 2011. View at Publisher · View at Google Scholar · View at Scopus
  156. W. C. Li, S. L. Ye, R. X. Sun et al., “Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3,” Clinical Cancer Research, vol. 12, no. 23, pp. 7140–7148, 2006. View at Publisher · View at Google Scholar · View at Scopus
  157. W. Yan, Y. Chang, X. Liang, et al., “High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases,” Hepatology, vol. 55, no. 6, pp. 1863–1875, 2012. View at Publisher · View at Google Scholar · View at Scopus
  158. C. Murdoch, M. Muthana, S. B. Coffelt, and C. E. Lewis, “The role of myeloid cells in the promotion of tumour angiogenesis,” Nature Reviews Cancer, vol. 8, no. 8, pp. 618–631, 2008. View at Publisher · View at Google Scholar · View at Scopus
  159. A. Weigert and B. Brüne, “Nitric oxide, apoptosis and macrophage polarization during tumor progression,” Nitric Oxide—Biology and Chemistry, vol. 19, no. 2, pp. 95–102, 2008. View at Publisher · View at Google Scholar · View at Scopus
  160. J. Rius, M. Guma, C. Schachtrup et al., “NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α,” Nature, vol. 453, no. 7196, pp. 807–811, 2008. View at Publisher · View at Google Scholar · View at Scopus
  161. C. Murdoch, A. Giannoudis, and C. E. Lewis, “Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues,” Blood, vol. 104, no. 8, pp. 2224–2234, 2004. View at Publisher · View at Google Scholar · View at Scopus
  162. H. J. Knowles, D. R. Mole, P. J. Ratcliffe, and A. L. Harris, “Normoxic stabilization of hypoxia-inducible factor-1α by modulation of the labile iron pool in differentiating U937 macrophages: effect of natural resistance-associated macrophage protein 1,” Cancer Research, vol. 66, no. 5, pp. 2600–2607, 2006. View at Publisher · View at Google Scholar · View at Scopus
  163. T. Schioppa, B. Uranchimeg, A. Saccani et al., “Regulation of the chemokine receptor CXCR4 by hypoxia,” The Journal of Experimental Medicine, vol. 198, no. 9, pp. 1391–1402, 2003. View at Publisher · View at Google Scholar · View at Scopus
  164. D. J. Ceradini, A. R. Kulkarni, M. J. Callaghan et al., “Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1,” Nature Medicine, vol. 10, no. 8, pp. 858–864, 2004. View at Publisher · View at Google Scholar · View at Scopus
  165. T. Cramer, Y. Yamanishi, B. E. Clausen et al., “HIF-1α is essential for myeloid cell-mediated inflammation,” Cell, vol. 112, no. 5, pp. 645–657, 2003. View at Publisher · View at Google Scholar · View at Scopus
  166. A. L. Doedens, C. Stockmann, M. P. Rubinstein et al., “Macrophage expression of hypoxia-inducible factor-1α suppresses T-cell function and promotes tumor progression,” Cancer Research, vol. 70, no. 19, pp. 7465–7475, 2010. View at Publisher · View at Google Scholar · View at Scopus
  167. H. Z. Imtiyaz, E. P. Williams, M. M. Hickey et al., “Hypoxia-inducible factor 2α regulates macrophage function in mouse models of acute and tumor inflammation,” The Journal of Clinical Investigation, vol. 120, no. 8, pp. 2699–2714, 2010. View at Publisher · View at Google Scholar · View at Scopus
  168. C. WeiXing, H. Tiantian, N. Qun, Y. Chaohui, and X. Ping, “Inhibitory effect of Hypoxia inducible factor-1 antisense oligonucleotide on growth of human hepatocellular carcinoma cells,” Medical Oncology, vol. 25, no. 1, pp. 88–92, 2008. View at Publisher · View at Google Scholar · View at Scopus
  169. F. Liu, P. Wang, X. Jiang et al., “Antisense hypoxia-inducible factor 1α gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma,” Cancer Science, vol. 99, no. 10, pp. 2055–2061, 2008. View at Publisher · View at Google Scholar · View at Scopus
  170. A. L. Cheng, Y. K. Kang, Z. Chen et al., “Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial,” The Lancet Oncology, vol. 10, no. 1, pp. 25–34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  171. A.-L. Cheng, Z. Guan, Z. Chen, et al., “Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial,” European Journal of Cancer, vol. 48, no. 10, pp. 1452–1465, 2012. View at Publisher · View at Google Scholar · View at Scopus
  172. W. Zhang, X. D. Zhu, H. C. Sun et al., “Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects,” Clinical Cancer Research, vol. 16, no. 13, pp. 3420–3430, 2010. View at Publisher · View at Google Scholar · View at Scopus